Actinium Pharmaceuticals, Inc. (ATNM) vs BRIACELL THERAP (BCTX)

Actinium Pharmaceuticals, Inc. and BRIACELL THERAP are both Biotechnology companies. Actinium Pharmaceuticals, Inc. and BRIACELL THERAP are of similar size ($37.4M and $37.2M). BRIACELL THERAP trades at the lower P/E: 1.9× against 3.3×. Actinium Pharmaceuticals, Inc. has the higher net margin (32.2% vs 0.00%) and the higher return on invested capital (0.00% vs −3,311.0%). Across the 14 metrics below, Actinium Pharmaceuticals, Inc. leads on 9 and BRIACELL THERAP on 5.

Valuation

Metric ATNM BCTX Biotechnology median
P/E 3.33 1.94 7.88
P/S 1.07 n/m 11.47
P/B 1.24 1.34 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.17 n/m 0.74
EV/Sales 0.05 n/m 10.73
Earnings yield 30.00% 51.65% (28.84%)
Free cash flow yield (61.70%) (100.28%) (23.03%)

Profitability

Metric ATNM BCTX Biotechnology median
Gross margin 98.71% 0.00% 65.16%
Operating margin 27.20% 0.00% 0.00%
Net margin 32.18% 0.00% 0.00%
Free cash flow margin (66.16%) 0.00% 0.00%
Return on equity 45.86% (173.55%) (57.72%)
Return on assets 21.92% (139.20%) (49.22%)
Return on invested capital 0.00% (3,311.00%) 0.00%

Growth

Metric ATNM BCTX Biotechnology median
Revenue growth (TTM) 2,731.18% — 5.64%
EPS growth (last fiscal year) 14.17% (43.04%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATNM BCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.08 7.07 4.73
Net debt to EBITDA 1.35 0.66 0.96

Dividend

Metric ATNM BCTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ATNM BCTX Biotechnology median
Market cap 37.42m 37.24m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack